共 22 条
- [22] How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)